David A. Siegel Travere Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TVTX
# of Institutions
185Shares Held
90.4MCall Options Held
305KPut Options Held
184K-
Black Rock Inc. New York, NY7.64MShares$143 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$141 Million0.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$138 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$129 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.48MShares$84 Million1.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.2B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...